Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alirocumab in Healthy Chinese Subjects: A Randomized, Double-Blind, Placebo-Controlled, Ascending Single-Dose Study

BACKGROUND: The addition of alirocumab (a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9 [PCSK9]) to background statin therapy provides significant incremental low-density lipoprotein cholesterol (LDL-C) lowering and cardiovascular event risk reduction. OBJECTIVES:...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Cardiovasc Drugs
Main Authors: Li, Haiyan, Wei, Yudong, Yang, Zhenhua, Zhang, Shuang, Xu, Xiuxiu, Shuai, Mengmeng, Vitse, Olivier, Wu, Yiwen, Baccara-Dinet, Marie T., Zhang, Yi, Li, Jianyong
Formato: Artigo
Idioma:Inglês
Publicado em: Springer International Publishing 2020
Assuntos:
Original Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7548281/
https://ncbi.nlm.nih.gov/pubmed/32080823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40256-020-00394-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados